Clarissa Diniz

About Clarissa Diniz

Dynamic and results-driven leader with a deep passion for bringing transformative therapies to patients living with rare diseases and rare cancers. With a proven track record across a spectrum of marketing, commercial, strategic, and operational roles, I consistently deliver breakthrough results in highly complex and diverse business environments. My expertise spans the entire lifecycle of product development, from pre-launch, early access, and commercialization to post-launch initiatives, across multiple global markets, including the US, Global, EMEA, and LATAM. I have successfully led the launch of four accelerated approval therapies over the past five years, driving strong market adoption of groundbreaking rare disease and oncology products. My strength lies in building and nurturing strategic relationships and navigating the intricacies of specialized markets with cultural agility and a proactive, solution-oriented mindset, consistently exceeding goals.With a comprehensive understanding of the drug discovery and development process, I am experienced in business development, licensing, alliance management, and compliance. My close collaboration with R&D teams allows me to translate complex scientific concepts into actionable commercial strategies. Additionally, I have an in-depth knowledge of intellectual property and a strong track record in government affairs. I am also deeply engaged with patient advocacy organizations, working globally to bridge the gap between innovation and patient needs, driving value for both patients and businesses.Skills: Rare Diseases | Oncology | New Product Planning | Marketing (consumer, health care provider, population health decision makers)| Brand Positioning | Brand Strategy |Strategic and Tactical Planning| Commercial Strategy | Market Access |Commercial Strategy | Commercial Operations |KOL Engagement | US, GLOBAL, EMEA, LATAM | Languages:Portuguese | SpanishGerman A1 levelPre-launch, launch experience:Rare diseases:Amondys 45® (casimersen), Vyondys 53® (golodirsen), Exondys 51® (eteplirsen) and Translarna (ataluren). I have worked on commercial planning and market shaping for gene therapy, notably Elevidys (delandistrogene moxeparvovec) for Duchenne muscular dystrophy.Experience in these disease states:NSCLC EGFR exon20i, NSCLC ALK+, Glioblastoma, Non-Hodgkin lymphoma (NHL), MPS1, HAE, CML, Peripheral T-cell lymphoma

Experience

1. Value & Access Innovation Strategy - Marketing

   Boehringer Ingelheim

   Aug 2023 — Present · New York, NY, US

   Value & Access launch lead, value access strategy for HERNEXEOS (zongertinib tablets)- a novel oral therapy targeting HER2 (ERBB2) mutant mNSCLC

Education

• Seton Hall University School of Law

  Master of Science in Jurisprudence, Health Law, Technology Law and Intellectual Property

• Marymount Manhattan College

  Political Science, Social Sciences

Skills

• Intellectual Property
• Biotechnology
• Orphan Drugs
• Life Sciences
• International Law
• Marketing Strategy
• Latin America
• Public Relations
• Business Development
• Patient Advocacy
• Oncology
• Entrepreneurship
• Management
• Governmental Affairs
• International Strategy
• Contract Negotiation
• Start-Ups
• Strategic Planning
• Global Product Management
• International Relations
• Product Launch
• Pharmaceutical Industry
• Due Diligence
• Strategy